Study of a single intra-articular injection of EVI-01 for the treatment of symptomatic knee osteoarthritis

The research company Aptissen SA is conducting the clinical trial EVI-01-IT Safety Study.

Prospective, single arm, pilot study to assess the safety and tolerability of a single intra-articular injection of EVI-01 for the treatment of symptomatic knee osteoarthritis.

It is planned to include 24 participants.

Actual study start date is June 6, 2022. The researchers expect to complete the study by June 2023.

One primary outcome measure is Safety and tolerability, Primary objective of this study is to assess the safety and tolerability of EVI-01 following single intraarticular administration in the knee joint, assessed with adverse events monitoring throughout the follow up duration of six months.

Further details can be found here https://ichgcp.net/clinical-trials-registry/NCT05422976 or https://clinicaltrials.gov/ct2/show/NCT05422976.

Clinical Research News

Upcoming Clinical Trials